Drug combo and targeted radiation for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (disitamab vedotin and sintilimab) plus radiation for people with HER2-positive advanced stomach cancer that has worsened after two prior treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced stomach cancer that is HER2-positive (a certain protein marker).
- You have tried and failed or could not tolerate at least two standard treatments.
- You have at least one tumor that can be measured on scans, plus two other tumors that can be treated with radiation.
- Your liver function is good (Child-Pugh class A).
- Your blood counts and organ function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests a combination of three drugs (targeted therapy, immunotherapy, and chemotherapy) before and after surgery for locally advanced HER2-positive stomach cancer. It aims to see if this treatment can improve outcomes for patients whose cancer has not yet spread.
This trial tests a combination of three drugs (Disitamab Vedotin, Tunlametinib, and a PD-1 antibody) for advanced stomach cancer that has HER2 protein. It is for patients who have tried at least two prior treatments or cannot tolerate standard therapy.
This trial is testing a new combination of drugs (targeted therapy plus immunotherapy plus chemotherapy) for people with a specific type of advanced stomach cancer called HER2-low. The goal is to see if this combination works better than the current standard immunotherapy plus chemotherapy.
Hear when a new HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.